Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes. (Q37337300)
Jump to navigation
Jump to search
scientific article published on 04 October 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes. |
scientific article published on 04 October 2015 |
Statements
Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes (English)
S Canecki Varžić
M Sargin
S Macura
J Zacho
J S Christiansen
17 November 2015
1 reference
1 reference
1 reference